Fig. 4.

Plasma glucose at baseline and 6 h after the infusion of exogenous placebo (a), GIP (b), GLP-1 (c) and GIP + GLP-1 (d) in individuals with type 2 diabetes in whom fasting hyperglycaemia was provoked by the omission of the long-acting insulin injection the night before each study (crossover design). Insulin (e) and glucagon (f) responses are also shown as AUCs above (insulin) and below (glucagon) baseline concentrations. Data are redrawn from Mentis et al [41]. Plasma glucose at baseline was not significantly different between the different study days (p=0.59), while plasma glucose concentrations at the end of the experiments differed significantly: placebo vs GIP, p=0.71; placebo vs GLP-1, p<0.001; placebo vs GIP + GLP-1, p<0.001; GIP vs GLP-1, p<0.001; GIP vs GIP + GLP-1, p<0.001; GLP-1 vs GIP + GLP-1, p>0.99. For the other comparisons, *p<0.05. Overall p values are presented for ANOVA comparing all experimental conditions